ARTICLE | Company News
UCB, Syndax deal
July 11, 2016 7:00 AM UTC
UCB granted Syndax exclusive, worldwide rights to cancer candidate UCB6352 (now SNDX-6352), a mAb against colony-stimulating factor 1 receptor ( CSF1R; C-FMS; CD115) that is expected to enter the ...